An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial

BACKGROUND: The number of injections in the dose escalation of subcutaneous immunotherapy (SCIT) is small for some currently used hypoallergenic allergoids, but can still be inconvenient to patients and can impair compliance. The aim of this trial was to compare safety and tolerability of an acceler...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaker, A. M., Al-Kadah, B., Luther, U., Neumann, U., Wagenmann, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736162/
https://www.ncbi.nlm.nih.gov/pubmed/26839682
http://dx.doi.org/10.1186/s13601-016-0093-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736162/
https://www.ncbi.nlm.nih.gov/pubmed/26839682
http://dx.doi.org/10.1186/s13601-016-0093-z

Ejemplares similares